GE HealthCare Technologies Inc. is a leading global innovator in medical technology, pharmaceutical diagnostics, and digital solutions . The company operates through four main business segments, offering a wide range of products that support various clinical specialties . These segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, each contributing significantly to the company's overall operations .
-
Imaging - Offers a comprehensive range of products including Molecular Imaging, Computed Tomography, Magnetic Resonance, Image-Guided Therapies, Women’s Health, and X-ray, supporting clinical specialties such as oncology, cardiology, and neurology .
- Molecular Imaging
- Computed Tomography
- Magnetic Resonance
- Image-Guided Therapies
- Women’s Health
- X-ray
-
Ultrasound - Provides solutions for Radiology and Primary Care, Women’s Health, Cardiovascular, and Surgical Visualization and Guidance .
-
Patient Care Solutions (PCS) - Encompasses Patient Monitoring, Anesthesia and Respiratory Care, Diagnostic Cardiology, and Maternal Infant Care .
- Patient Monitoring
- Anesthesia and Respiratory Care
- Diagnostic Cardiology
- Maternal Infant Care
-
Pharmaceutical Diagnostics (PDx) - Includes Contrast Media and Molecular Imaging business lines, enhancing the diagnostic value of imaging exams .
- Contrast Media
- Molecular Imaging
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Peter J. Arduini ExecutiveBoard | President, Chief Executive Officer, and Director | Board Member at Bristol-Myers Squibb Company; Chairman of the Board at AdvaMed; Director at National Italian American Foundation | Appointed as President and CEO of GEHC in December 2022. Previously CEO of Integra LifeSciences. | |
Adam Y. Holton Executive | Chief People Officer | Board Member at Sierra Delta | Joined GEHC in June 2024. Previously Chief People Officer at Amedisys. | |
Frank R. Jimenez Executive | General Counsel and Corporate Secretary | Board Member at Huntington Ingalls Industries, Equal Justice Works, Yale Law School Fund; Advisory Boards at Columbia University, Yale Law School, University of Miami, National Security Institute | Appointed upon GEHC's spin-off in early 2023. Extensive legal experience. | |
James K. Saccaro Executive | Vice President and Chief Financial Officer | None | Joined GEHC as CFO in June 2023. Previously CFO at Baxter International Inc. | |
Kenneth Stacherski Executive | Chief Global Supply Chain and Service Officer | None | Serving since the Spin-Off in 2023. Previously COO at Array Technologies. | |
Kevin M. O’Neill Executive | President and CEO, Pharmaceutical Diagnostics | None | Serving since 2017, continued role post-spin-off. Previously CFO, Life Sciences Division. | |
Philip Rackliffe Executive | President and CEO, Advanced Visualization Solutions | None | Joined GEHC in July 2024. Previously CEO of IGT business at GEHC. | |
Roland Rott Executive | President and CEO, Imaging | None | Joined GE in 2011, CEO of Ultrasound before Imaging. Entrepreneurial background. | |
Taha Kass-Hout Executive | Chief Science and Technology Officer | Chair of the AdvaMed Digital Health Tech Division Board of Directors | Joined GEHC on January 3, 2023. Previously VP of Machine Learning at Amazon. | |
Thomas J. Westrick Executive | President and CEO, Patient Care Solutions | Dean’s Advisory Board for the Wisconsin School of Business | CEO of Patient Care Solutions since September 2020. Previously led Global Quality and Regulatory Affairs. | |
Anne T. Madden Board | Director | Senior VP and General Counsel at Honeywell; Director at Quantinuum | Director since December 2022. Extensive M&A experience at Honeywell. | |
Catherine Lesjak Board | Director | Director at General Electric, PROS Holdings, SunPower Corporation; Advisory Board Member at Haas School of Business | Director since December 2022. Former CFO at HP Inc. | |
H. Lawrence Culp, Jr. Board | Chairman | Chairman and CEO of General Electric; CEO of GE Aerospace | Chairman of GEHC since December 2022. Also leads GE and GE Aerospace. | |
Phoebe L. Yang Board | Director | Board Member at Doximity, Inc.; Board Trustee at CommonSpirit Health; Member of the Council on Foreign Relations | Director since the Spin-Off. Former GM at Amazon Web Services, Healthcare. | |
Risa Lavizzo-Mourey Board | Lead Director | Board Member at Intel, Merck, Better Therapeutics; Chair of Smithsonian Institution Board of Regents; Governor of TIAA; Trustee of Howard Hughes Medical Institute | Lead Director since the spin-off. Former CEO of Robert Wood Johnson Foundation. | |
Rodney F. Hochman Board | Director | President and CEO of Providence; Board Member of Diversey Holdings, Ltd. | Director since the Spin-Off. CEO of Providence. | |
Tomislav Mihaljevic Board | Director | CEO and President of Cleveland Clinic; Board Co-Chair of US-UAE Business Council | Director since the Spin-Off. CEO of Cleveland Clinic. | |
William J. Stromberg Board | Director | Non-Executive Chair of T. Rowe Price Group; Trustee at Johns Hopkins University | Director since the Spin-Off. Former CEO of T. Rowe Price Group. |
- Given the ongoing delays in China's stimulus funding and the slow recovery you've observed, how confident are you in your mid-term revenue and margin projections, and what specific strategies are you implementing to mitigate prolonged delays in China?
- You've raised the low end of your adjusted EPS guidance despite challenges in China; what gives you confidence in achieving this guidance, and what levers can you pull if conditions in China do not improve as anticipated?
- You anticipate Flyrcado could generate over $500 million annually once infrastructure is in place; can you elaborate on the timeline and key challenges in building out the necessary health system capacity, and how might delays impact your growth expectations?
- With the expected launch of Flyrcado in late Q1 2025 and ongoing work around commercialization, reimbursement, and CMS approvals, what risks could potentially delay the launch or affect the adoption rates of this product?
- Despite strong performance in the U.S. and PDx, your organic revenue growth was only 1% this quarter; what specific strategies are you pursuing to drive higher growth rates amid China headwinds and competitive pressures in the imaging equipment market?
Research analysts who have asked questions during GE HealthCare Technologies earnings calls.
David Roman
Goldman Sachs Group Inc.
4 questions for GEHC
Joanne Wuensch
Citigroup Inc.
4 questions for GEHC
Robert Marcus
JPMorgan Chase & Co.
4 questions for GEHC
Vijay Kumar
Evercore ISI
4 questions for GEHC
Larry Biegelsen
Wells Fargo & Company
3 questions for GEHC
Anthony Petrone
Mizuho Group
2 questions for GEHC
Craig Bijou
Bank of America Securities
2 questions for GEHC
Jason Bednar
Piper Sandler Companies
1 question for GEHC
Lawrence Biegelsen
Wells Fargo
1 question for GEHC
Matthew Taylor
Jefferies
1 question for GEHC
Matt Taylor
Jefferies & Company Inc.
1 question for GEHC
Navann Ty Dietschi
BNP Paribas
1 question for GEHC
Rick Wise
Stifel Financial Corp
1 question for GEHC
Ryan Zimmerman
BTIG
1 question for GEHC
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Siemens Healthineers | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Siemens Healthineers. |
Philips Healthcare | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Philips Healthcare. |
The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Canon. | |
Mindray | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Mindray. |
United Imaging | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include United Imaging. |
Bayer | In our PDx business segment, we primarily compete with Bayer. |
Bracco | In our PDx business segment, we primarily compete with Bracco. |
Guerbet | In our PDx business segment, we primarily compete with Guerbet. |
In our PDx business segment, we primarily compete with Lantheus. | |
Curium | In our PDx business segment, we primarily compete with Curium. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MIM Software Inc. | 2024 | Acquired on April 1, 2024 for approximately $259 million upfront with additional potential earn-out and contingent payments totaling up to $36 million; the deal was funded with cash on hand and accounted for as a business combination, with key purchase price allocations including goodwill ($195 million) and other intangibles that enhance GE HealthCare’s imaging and AI solutions. |
Caption Health, Inc. | 2023 | Completed on February 17, 2023, this acquisition involved a $127 million upfront payment, a $10 million holdback, and potential earn-out payments of $13 million; it was structured as a business combination with significant purchase price allocations—goodwill of $94 million and intangible assets of $60 million—to bolster GE HealthCare’s Ultrasound segment with AI-guided ultrasound technology. |
IMACTIS SAS | 2023 | Announced in Q2 2023 as a tuck-in acquisition for a French company specializing in electromagnetic navigation for CT procedures; while the financial terms were not disclosed, the deal strategically strengthens GE HealthCare's CT interventional guidance capabilities and fits its push toward enhanced precision care. |
Recent press releases and 8-K filings for GEHC.
- Revenues of $5.1 billion, up 6% reported and 4% organic year-over-year, driven by strength in EMEA and the U.S.
- Organic orders growth of 6% with a book-to-bill ratio of 1.06×, reflecting broad demand across all segments
- Net income margin of 8.7% (down 100 bps), adjusted EBIT margin of 14.8% (down 150 bps); diluted EPS $0.98, adjusted EPS $1.07
- Operating cash flow of $593 million and free cash flow of $483 million for the quarter
- Raised lower end of full-year 2025 adjusted EPS guidance to $4.51–4.63 and reaffirmed all other full-year metrics
- GE HealthCare delivered $5.1 B in revenue, with 4% organic growth, 6% organic orders growth and a book-to-bill of 1.06x.
- Adjusted EBIT was $761 M (14.8% margin, down 150 bps YoY) and adjusted EPS was $1.07, a 6% decline driven by tariff headwinds of $0.16 per share.
- Free cash flow totaled $483 M, down $168 M YoY, reflecting higher receivables and tariff payments of approximately $95 M.
- The company reaffirmed its 2025 outlook and raised the lower end of adjusted EPS guidance to $4.51–$4.63, while maintaining revenue, margin and free cash flow targets.
- Revenues of $5.1 billion rose 6% reported and 4% organic; organic orders grew 6% with a book-to-bill of 1.06
- Net income margin was 8.7% (down 100 bps) and Adjusted EBIT margin was 14.8% (down 150 bps) year-over-year
- Diluted EPS of $0.98 and Adjusted EPS of $1.07, versus $1.02 and $1.14 in Q3 2024
- Operating cash flow of $593 million and Free cash flow of $483 million, down 20% and 26% respectively
- Raised the lower end of full-year 2025 Adjusted EPS guidance to $4.51–$4.63 and reaffirmed other metrics
- CE mark received for the Carevance™ patient monitor, expanding access in Europe.
- Platform leverages 50+ years of GE HealthCare’s clinical monitoring expertise with proprietary algorithms and proven technologies.
- Introduces Cardiac Output Insights for on-device, real-time support in managing perioperative hemodynamic instability.
- Designed to streamline acute-care workflows with improved in-hospital transport support and continuous patient data.
- Aims to mitigate perioperative hypotension risks, potentially reducing complications and hospital stay duration.
- GE HealthCare’s Carevance patient monitoring platform received CE marking, enabling roll-out in Europe.
- Built on over 50 years of clinical monitoring expertise, the platform uses proprietary algorithms for advanced ICU patient support and improved intra-hospital transport workflow.
- Introduces Cardiac Output Insights, a real-time device feature to help clinicians manage perioperative hypotension and hemodynamic instability.
- Aims to reduce post-surgical complications and lengthy hospital stays by enabling timely interventions.
- Carevance received CE marking, offering advanced, real-time patient monitoring leveraging GE HealthCare’s 50-year clinical expertise for ICU and intra-hospital transport workflows.
- Introduces Cardiac Output Insights, enabling non-invasive, on-device hemodynamic monitoring to detect and manage perioperative hypotension with real-time graphical decision support.
- Integrates proprietary algorithms like EK-Pro to reduce ECG false alarms by up to 92%, enhancing operational efficiency and data reliability in critical care settings.
- Expands GE HealthCare’s modular surveillance portfolio, providing a flexible solution that balances clinical excellence with cost accessibility across diverse hospital environments.
- GE HealthCare erhält CE-Kennzeichnung für die Carevance-Plattform, um in Europa den Zugang zu fortschrittlicher Patientenüberwachung und perioperativem Hypotonie-Management zu erweitern.
- Plattform integriert die neue Cardiac Output Insights-Funktion für nicht-invasive Echtzeit-Überwachung des Herzzeitvolumens ohne zusätzliche Hardware.
- Carevance nutzt proprietäre Algorithmen und bewährte Technologien zur Verbesserung klinischer Entscheidungen und kann EKG-Fehlalarme um bis zu 92 % reduzieren.
- Teil des modularen Überwachungsportfolios von GE HealthCare; Vorstellung auf dem ESICM-Kongress im Oktober 2025 unterstreicht Fokus auf skalierbare, kosteneffiziente Patientenversorgung.
- Vector Capital has signed an agreement to acquire Showpad, an AI-driven sales enablement leader based in Chicago and Ghent.
- Upon closing (expected in 2025), Showpad will merge with Bigtincan Holdings (acquired April 2025) under the Showpad brand, combining global R&D and resources.
- Showpad serves clients in 50+ countries—including Coca-Cola, Dow, DuPont and GE Healthcare—and is recognized in Forrester Wave™ and Gartner Peer Insights™ reports.
- Insight Partners will reinvest its stake in the new entity; the deal remains subject to customary regulatory approvals.
- GE HealthCare topped the FDA’s AI-enabled medical device authorizations list for the 4th consecutive year, reaching 100 approvals to date.
- The company increased R&D investments to integrate AI across its devices, aiming to boost productivity, efficiency, and diagnostic confidence, with a goal of securing over 200 authorizations by 2028.
- Its AI-enabled solutions span imaging modalities and care pathways—including oncology, cardiology, and neurology—addressing customer challenges and driving orders and revenue growth.
- GE HealthCare emphasizes responsible AI principles—safety, validity, transparency, explainability, and fairness—at every stage of product development to support long-term growth.
- AI-driven healthcare market projected to top $110 billion by 2030, with potential to unlock $461 billion in additional value by 2035
- GE HealthCare Technologies unveiled LesionID™ Pro at SNMMI 2025, featuring zero-click pre-processing for faster, more accurate tumor burden analysis
- The company is expanding its theranostics portfolio, integrating AI-powered imaging technologies, radiopharmaceuticals, and workflow tools to personalize cancer care